Literature DB >> 833472

Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.

S M Grundy, H Y Mok.   

Abstract

Studies were carried out to determine effects of combined chemotherapy in patients with hyperlipidemia. In one study, 14 patients were treated first with colestipol and then with the combination of colestipol and clofibrate. In a second study, six patients were given clofibrate followed by addition of phytosterols. The following measurements were made in most patients: (1) plasma lipid concentrations, (2) fecal excretions of neutral steroids and bile acids, and (3) lipid composition of gallbladder bile. In six patients of the first study, hepatic secretion rates of biliary lipids and pool sizes of bile acids were also estimated. In the first study, colestipol alone caused a marked increase in fecal bile acids that resulted in a sizable decrease in plasma cholesterol concentrations (average 21 percent). In several patients, however, triglycerides were increased somewhat by colestipol. Despite interruption of the enterohepatic circulation of bile acids, the bile acid pool was not reduced, since a compensatory increase took place in bile acid synthesis. Also, except in one patient who developed gallstones following institution of colestipol, saturation of gallbladder bile with cholesterol was not markedly increased by this drug alone. Addition of clofibrate frequently produced a further decrement in plasma cholesterol, and the mild hypertriglyceridemia induced by colestipol was reversed. However, colestipol plus clofibrate usually caused a striking increase in saturation of gallbladder bile. Previous studies have shown that clofibrate causes a flux of cholesterol from tissue pools by simultaneously decreasing cholesterol synthesis and increasing its excretion. To further increase cholesterol excretion, phytosterols, which block cholesterol absorption, were added to clofibrate in the second study. Although phytosterols did not cause a further reduction in plasma cholesterol in these particular patients, they nevertheless greatly enhanced cholesterol excretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833472

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

Authors:  J Shepherd; C J Packard; J M Stewart; R F Atmeh; R S Clark; D E Boag; K Carr; A R Lorimer; D Ballantyne; H G Morgan
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

2.  Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism.

Authors:  K Einarsson; S Ericsson; S Ewerth; E Reihnér; M Rudling; D Ståhlberg; B Angelin
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Prevalence of gallbladder disease in hyperlipoproteinemia.

Authors:  J Ahlberg; B Angelin; K Einarsson; K Hellström; B Leijd
Journal:  Dig Dis Sci       Date:  1979-06       Impact factor: 3.199

4.  Effect of dietary animal and vegetable protein on gallstone formation and biliary constituents in the hamster.

Authors:  S Mahfouz-Cercone; J E Johnson; G U Liepa
Journal:  Lipids       Date:  1984-01       Impact factor: 1.880

Review 5.  Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-03       Impact factor: 9.546

6.  Bile lipid composition and bile acid pool size in diabetes.

Authors:  M P de Leon; R Ferenderes; N Carulli
Journal:  Am J Dig Dis       Date:  1978-08

Review 7.  The effect of drugs on bile flow and composition. An overview.

Authors:  L Okolicsanyi; F Lirussi; M Strazzabosco; R M Jemmolo; R Orlando; G Nassuato; M Muraca; G Crepaldi
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

8.  Effects of a salt of cholestyramine and 2-[4-(p-chlorobenzoyl)phenoxy]2-methyl propionic acid (alpha-1081) on biliary lipid secretion in rats.

Authors:  R Aldini; L Barbara; A Benelli; V Borzatta; S Geminiani; G Mascellani; A Morselli; A Roda; E Roda
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

9.  Modification of the carcinogenic process in colorectal cancer by endogenous and exogenous factors: effect of colestipol hydrochloride on tumors induced by dimethylhydrazine.

Authors:  J P Daugherty
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.